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Abstract
We are facing serious coronavirus disease-19 pandemic, caused by the severe acute respiratory syndrome 
coronavirus-2. Among infected individuals, there is a higher prevalence of the cardiovascular disease, which leads 
to their poor prognosis. Myocardial injury is present in more than 15% of critical ill patients in the form of acute 
myocardial dysfunction or subsequent myocardial injury that develops as disease severity. This new virus pandemic 
is a global challenge for health-care system which was we still have much to learn.
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Introduction
The coronavirus disease 19 (COVID-19) 
pandemic has opened up several serious challenges 
to the world. It changed our lives in several ways. The 
pandemic has put enormous pressure on health-care 
systems worldwide. Changes in the medical system 
with unchanged and insufficient financial and medical 
resources were unexpected. Hospitals in China, Italy, 
Spain, and now the United States as the most affected 
countries have faced huge numbers of critically ill patients 
with COVID-19, which leads to the reduction of hospital 
resources, infection of medical personnel, and shortages 
of vital resources especially in intensive care units [1]. 
The experiences and numbers coming from those 
regions have put developing countries in the position of 
serious alerts and even more fear of the final health and 
economic impact of the COVID-19 pandemic. There are 
many unknown puzzles the virus imposes to us as medical 
professionals. Each day we are gaining new information’s 
concerning the clinical expressions and course of the 
disease that significantly influence the actual therapy we 
use. Most data we have come from China, Italy, France, 
and recently the USA and management is guided by 
the expert opinion. We do not have randomized studies 
due to recent infection or control groups of patients due 
to ethical reasons. We learn every day on the virus that 
forces us to change our health and social directions.
Methods
The investigators review and summarize the 
latest and evolving scientific data regarding evidence 
linking COVID-19 with increased cardiovascular 
morbidity and mortality. The authors conducted a 
search of the relevant articles from various databases, 
namely, PubMed and SCOPUS science, direct for the 
latest published papers. We also search for expert 
opinions important for the review paper.
Global burden of COVID-19 pandemic
COVID-19 is now a global pandemic. Outbreak 
of pneumonia caused by a new coronavirus occurred 
in Wuhan in December 2019 and has rapidly spread 
throughout China and the rest of the world [2], [3]. After 
virus identification and isolation, the pathogen for this 
pneumonia was originally called 2019 novel coronavirus 
(2019-nCoV) but has been officially named severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) by 
the World Health Organization (WHO). On January 
30, 2020, the WHO declared the outbreak of SARS-
CoV-2. On February 11, 2020, the WHO announces 
“COVID-19” as the name of new disease [3], [4]. Before 
December 2019, the virus was unknown to science. As 
of April 12, 2020, there were more than 1.846.983 cases 
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worldwide, with nearly 113.885 case-fatalities in a total 
of 210 countries. Although COVID-19 predominantly 
affects lung function, it affects the cardiovascular 
system on multiple levels, increasing morbidity in 
patients with underlying cardiovascular disease (CVD) 
and provoking myocardial injury and dysfunction [5]. 
Patients with established heart disease constitute a 
particularly challenging group, as many of them have 
conditions that may be life-threatening if intervention 
is inadequately delayed. Even with the treatment 
evidence we have today, those patients have increased 
risk for complications and unfavorable disease courses.
COVID-19 case fatality rate (CFR, number of 
deaths/numbers of those diagnosed) is significantly 
different around the world. The original reports from China 
are referring a CFR of 2.3% with lower symptomatic 
case fatality risk of 1.4%, which is much different from 
influenza (0.1%), Middle East respiratory syndrome 
(34%), and SARS (10%) [6]. Based on reported data 
from April 12, 2020, the global number of COVID-19 
cases is 1.846.983, with 113.885 deaths and 421.898 
patients recovered. The CFR varies significantly by 
country: China reported 4.4% death rate (82,052 cases), 
Italy 8.5% (156,363 cases), Spain 8.9% (116,127 cases), 
Germany 6.9% (127,57 cases), and the United States 
30% (557,217 cases) [7]. The CFR rises rapidly with 
increasing age. The CFR is <1% for individuals under 
50 years of age, rising to 3.6% for 60 years old and up to 
14.8% for octogenarians. In addition, the CFR increases 
with disease severity, with CFR of around 50% among 
critical patients. Patients with several comorbidities have 
significantly increased CFR: 10.5% for CVD; 7.3% for 
diabetes mellitus; 6.3% for chronic obstructive pulmonary 
disease; 6% for hypertension; and 5.6% for patients with 
cancer [8]. The mortality numbers have region and time 
differences and are influenced by the volume of testing, 
the quality of healthcare system, disease treatment, time 
since initial outbreak, and population characteristics 
such as age, sex, and population health (Figure 1).
COVID-19 in humans: Virus spread, signs, 
and symptoms
The novel COVID-19 virus is a singe-stranded 
enveloped RNA virus, the seventh so far known human 
coronavirus (Figure 2). It is assumed to have originated 
from bats, then moved from bats to an intermediate host 
and then to humans [9]. Coronaviruses have capacity 
for rapid mutation and recombination.
COVID-19 is spreading mostly through 
respiratory droplets but also can be aerosolized or 
detected in the stool. There is a high viral load in both 
symptomatic and asymptomatic patients, meaning the 
asymptomatic spread between person to person is 
likely, with secondary infection rates ranging up to 5%. 
The incubation period is believed to be between 2 and 
14 days and up to 98% of individuals will experience 
symptoms within 11.5 days of exposure [10]. The virus 
has been demonstrated to remain stable for up to 3 h in 
the aerosolized form, up to 24 h on cardboard and up 
to 72 h on plastic or stainless steel. Compared with an 
outbreak of SARS in 2003, caused by the SARS-CoV, 
COVID-19 has a stronger transmission capacity [11].
What we currently know is that COVID-19 
shows a wide range of manifestations and severity of the 
disease. Infection usually causes mild upper respiratory 
infections in younger individuals but may lead to 
hospitalization in elderly patients with underlying cardiac 
and lung disease. Initially predominantly affecting older 
individuals, now we are increasingly facing the spread 
of the disease among the younger population, with often 
unpredictable course of the disease, assumed to be 
caused by the individual immune response to the virus. 
The most common symptoms are fever (88%) and 
dry cough (67.7%), as in many other viral syndromes. 
Rhinorrhea (4.8%) and gastrointestinal symptoms 
(diarrhea 4–14%, nausea/emesis 5%) appear to be less 
frequent with COVID-19. In addition, reported symptoms 
are loss of smell and taste [12].
Reports we have from China shows that a 
significant majority of patients (81%) had mild symptoms 
(no pneumonia or mild pneumonia). Among those with 
more significant symptoms, 14% experienced severe 
symptoms and 5% were critical (respiratory failure, 
septic shock, and/or multiple organ dysfunction) [12].
COVID-19 and cardiovascular system
Published data about disease manifestation 
and progression showed that patients with underlying 
CVD are among the highest risk individuals for severe 
disease and death. In a series of 44 672 confirmed 
patients with COVID-19 from China, 14.2% were 
reported to have CVD [13]. About 22.7% of all deaths 
were in patients with underlying CVD [13].
It is even of a greater concern that COVID-19 
can cause cardiac injury in patients without underlying 
heart condition. Understanding the damage caused 
by COVID-19 to the cardiovascular system and the 
underlying mechanisms is of the greatest importance. 
This will allow timely and effective treatment of patients, 
meaning reduction of mortality.
A place of attachment of COVID-19 is believed 
to be angiotensin converting-enzyme 2 (ACE-2), a 
membrane-linked aminopeptidase and receptor through 
which the virus can potentially attach to the epithelial 
cells in the lungs, or to the myocardial cells and mediate 
tissue injury [14]. The expression level of ACE-2 is 
probably higher in diabetic and hypertensive individuals, 
which makes them prone to the infection with COVID-19.
Cardiac injury – elevated cardiac troponin
The data from published studies showed 
that patients with myocardial injury (elevated cardiac 
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troponin) have higher hospital mortality, up to 3 
times [15]. About 50% of fatal cases have increased 
high-sensitivity cardiac troponin I during hospitalization, 
as shown in Table 1 [8]. Troponin elevation goes parallel 
to the elevation of N-terminal pro-B-type natriuretic 
peptide and C-reactive protein. It is obvious that troponin 
rise in the same time with the rise of other inflammatory 
biomarkers (D-dimer, ferritin, interleukin-6, and lactate 
dehydrogenase) speaks against isolated myocardial 
injury mediated through ACE-2. It might be a reflection 
of cytokine storm or secondary hemophagocytic 
lymphohistiocytosis.
Temporal changes in troponin levels show slow 
elevation of values first 2 weeks, and steep elevation 
3rd week in patients with a severe and critical form of 
the disease. During follow-up, the median hs- troponin I 
among survivors did not change significantly [8].
Cases of ST elevation (STEMI like) without 
coronary obstruction were published [16], [17] and 
explained as viral myocarditis or stress cardiomyopathy. 
However, until now, no signs of direct virus infiltration 
of the myocardium were published. The scientific 
data we have point towards inflammation as one of 
the mechanisms of the multi-organ damage in the 
course of the COVID-19 disease. Sporadic autopsy 
cases suggest infiltration of myocardium by interstitial 
mononuclear inflammatory cells [18].
The use of cardiac magnetic resonance 
imaging or endomyocardial biopsy may give more 
answers to these questions.
There is still no evidence of impaired heart 
function due to myocardial injury in patients who 
recover from COVID-19. They rather have normal 
heart function after full recovery. According to that, we 
may see the myocardial injury and troponin level as a 
marker of disease severity, related to cytokine storm, 
hypoxia, vasopressors, and coagulation disturbances. 
Monitoring and managing a myocardial injury is of utmost 
importance in severe and critically ill patients [15].
Troponin elevation in the context of COVID-19 
infection, in the absence of other signs and symptoms, 
suggesting acute coronary syndrome, should not a 
priority lead to invasive diagnostic procedures.
Heart failure
It is a challenge for every physician to make 
differential diagnoses between decompensated heart 
failure, often complicated with pulmonary infection and 
COVID-19 infection, before laboratory-confirmation. 
And more than that, chest computed tomography 
images of patients with decompensated heart failure 
are very similar to those with infection of COVID-19 [22]. 
Ground-glass opacity and thickening of interlobular 
septa are present in both cases, but patients with heart 
failure have a higher ratio of central versus gradient 
distribution [22].
Extreme elevations in natriuretic peptides with 
the cause of death attributed to cardiac failure and arrest 
are reported in up to 25% of case-fatality rates [8], [23]. 
In a large cohort from China, heart failure was reported 
in 23% of infected patients and the prevalence was 
significantly higher among non-survivors (52% vs. 12%, 
p < 0.0001) [8].
It is clear that patients with previous heart 
failure will have a more complicated pulmonary disease 
of any kind. However, during COVID-19 pandemic, 
fulminant myocarditis or cardiomyopathy presentations 
are observed. A hypothesis is proposed that underlying 
structural heart disease in early-stage (like heart failure 
with preserved ejection fraction) in the context of 
pulmonary complications and later in the form of acute 
systolic heart failure develops as a response to the 
cytokine phase of COVID-19.
Elderly patients with heart failure may have 
left ventricular hypertrophy, diastolic dysfunction, or 
systolic dysfunction. These patients are prone to higher 
pulmonary vascular pressure in the typical critical care 
scenario of overload with fluid infusions to maintain 
blood pressure as well as the administration of parenteral 
medications. The use of non-steroid anti-inflammatory 
drugs as well as secretagogues in diabetic patients, alter 
salt and water balance and may worsen cardiac function.
Coronary artery disease
Patients with coronary artery disease, stable, 
or unstable are prone to complications during COVID-
19 infection, due to coronary plaque rupture or stent-
thrombosis secondary to pro-coagulant effects of 
systemic inflammation.
The first autopsy of a 53-year-old woman with 
chronic renal failure in Jinyintan Hospital showed acute 
myocardial infarction [8]. About 5.8% of patients with 
severe/critical clinical presentation have a history of 
coronary heart disease, in comparison with 1.8% of 
those with non-severe illness [9].
It is important to emphasize that many COVID-
19 infected patients were presented to the doctor with 
heart palpitations and chest tightness, instead of fever 
and cough. Accompanied by ECG changes suggestive 
of ischemia, represent a trap for the doctors, to reduce 
cautions toward self-protection. Coronary arteries 
without coronary obstruction on angiography will raise 
the first suspicion of infection with COVID-19. However, 
elevated troponin during COVID-19 infection, if coupled 
with symptoms and signs of myocardial infarction, should 
lead to guideline-directed interventions, fibrinolysis, or 
coronary angioplasty in designated hospitals [24].
Treatment in the light of CVD
Regarding the treatment of the COVID-19 
infection until the beginning of April 2020, more than 
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300 clinical trials are ongoing. In the absence of 
proven effective therapy, supportive care, starting from 
symptomatic measures, up to complete intensive care 
support is recommended [25].
Figure 1:  Covid-19’s case fatality rate 
increases with age based on China’s data 
Robert Verity, Lancet Infect Dis. 2020 Mar 30. pii: S1473-
3099(20)30243-7. doi: 10.1016/S1473-3099(20)30243-7
The role of the pharmacologic renin-
angiotensin-aldosterone blockade, in patients with 
CVD and COVID-19 infection, needs more research, 
because the relationship seems to be very complex. 
Up to date, major health institutions and cardiology 
societies do not recommend discontinuation of ACE 
inhibitors or angiotensin II receptor (ARB) medications 
for all patients taking those medications for another 
cardiology indication. There is no evidence showing 
an increased risk of infection or worse clinical course 
in patients using these medications. However, there 
are strong warnings that discontinuation of drugs, 
proven to decrease mortality in patients with CVD,
Figure 2: COVID-19 structure  https://www.amercrystalassn.org/
may lead to excess mortality due to cardiovascular 
reasons.
In patients with heart failure, excessive fluid 
use and drugs that may alter salt and water balance, 
such as NSAID, should be avoided. Management 
of advanced heart failure should be guided by the 
cardiologist, having into consideration the hyper-
inflammation phase of the infection.
In patients with coronary artery disease 
and COVID-19 infection, use of plaque stabilizing 
agents (aspirin, statins, beta-blockers, and 
angiotensin-converting enzyme inhibitors) has been 
suggested as a possible therapeutic strategy [26]. 
Unnecessary diagnostic tests (cardiac troponin and 
echocardiography) should be minimized, or in some 
cases, avoided [27], [28], [29]. These tests should be 
used in the circumstances in which they could add to 
the management of patients with COVID-19.
Special care should be taken about the 
potential cardiovascular side-effects of various therapies 
used for treating the viral infection: Antiretroviral 
drugs, hydroxychloroquine, azithromycin, etc. Daily 
electrocardiographic monitoring of the QT interval is 
suggested [29].
Knowledge gaps and future directions
The pathobiology, clinical characteristics, 
and prognosis of the infection are still being studied. 
An early signal of myocardial injury (cardiac troponin 
elevation) and new heart failure as a consequence 
of it is recognized as a bad prognostic marker of the 
disease. Special caution should be taken in therapeutic 
management, drug interactions, and proarrhythmogenic 
potentials in some antiviral protocols.
The current evidence of the association 
between renin-angiotensin-aldosterone medications and 
ACE-2 levels with clinical outcome in COVID-19 infection 
is insufficient. More information needs to be generated.
COVID-19 has emerged as a new disease 
only a few months ago and it is impossible to discuss 
the long-term outcome in patients recovering from the 
infection. There is still no evidence of impaired heart 
function due to myocardial damage in the acute phase. 
Follow-up studies and more data are needed to make 
conclusions.
Conclusion
Preexisting CVD is common in patients with 
COVID-19 and those patients are at higher risk of 
Table 1: Comparison of hs-troponin I levels in severe/critically ill patients and non-critically ill patients
Authors No. of pts Acute cardiac injury (high troponin level) in severe/critical form of disease (ICU pts) Acute cardiac injury (high troponin level) in non-ICU pts p-value
Huang et al. [12] 41 pts 31% 4% p<0.01
Wang et al. [19] 138 pts 22,2% 2% p<0.01
Acute cardiac injury (high troponin level) in fatal cases Acute cardiac injury (high troponin level) in survivors
Zhou et al. [8] 191 pts 59% 1% p<0.01
He et al. [20] 54 pts 60.9% 25.8% p<0.0013
Shi et al. [21] 416 pts 51.2% 4.5% p<0.01
ICU: Intensive care unit
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morbidity and mortality. Myocardial injury is present 
in more than 15% of severely ill patients. Several 
promising treatments are under investigation, but 
so far none with the proven clinical efficacy. The 
continuation of clinically indicated ACEi or ARB therapy 
is recommended by many heart associations, based 
on the currently available evidence. We hope the near 
future will answer the remaining questions and prove 
the force we make each day to fight the virus.
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